Sponsor:
Merck Sharp & Dohme LLC
Code:
NCT07734610
Conditions
Severe Renal Impairment
Healthy
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Accepted
Interventions
Nemtabrutinib
Brief summary:
Conditions
Severe Renal Impairment
Healthy
Study ID
NCT07734610
Start date
Sep 17, 2026
Status verified date
Sep, 2026
Completion date
Feb 1, 2027
Anticipated
Primary completion date
Feb 1, 2027
Anticipated
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Accepted
Enrollment
20 participants
Anticipated
Intervention Model
Single group
Primary purpose
Treatment
Arms
experimental: Nemtabrutinib
Interventions
Nemtabrutinib
Primary outcome measure
Central contacts
Locations
Floridian Clinical Research, LLC ( Site 0001)
Recruiting
Miami Lakes, Florida, United States, 33016
Contacts
Study Coordinator
305-330-9977Sponsor
Merck Sharp & Dohme LLC
Last update posted
Sep 17, 2026
Last verified
Sep, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-18. This information was provided to ClinicalTrials.gov by Merck Sharp & Dohme LLC on 2026-09-17.